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                ABSTRACT 
 
Accumulated data suggest that a disrupted FGF23-Klotho axis is a major contributor to the 
development of chronic kidney disease (CKD). This axis might have a broader role in the 
regulation of inflammation, yet the underlying mechanisms remain largely elusive. To 
understand the biological actions of FGF23, it is important to elucidate the function of the 
receptors that mediate the FGF23 signaling. Klotho, a type I membrane-bound protein directly 
interacts with the FGF-receptor 1c and functions as a specific FGF23-receptor. FGF23-induced 
activation of the FGF receptor/Klotho complex exerts a reduction in re-absorption of phosphate 
as well as in the down-regulation in the synthesis of vitamin-D in renal tubules. In addition to its 
potential role in phosphate metabolism, Klotho might have a wider role in the regulation of 
inflammation; i.e., it has been shown that its production is substantially reduced in different 
inflammatory diseases such as acute kidney injury (AKI), CKD, inflammatory bowel disease 
(IBD), and rheumatoid arthritis (RA). The overall aim of the present research project is to 
elucidate the pathogenic mechanisms of the FGF23-Klotho axis in the development of CKD and 
hematopoietic stem cell transplantation (HSCT)-associated AKI.  
 
In order to understand the basic mechanisms underlying these conditions, we generated distal 
tubule-specific Klotho (Ksp-KL
-/-
) using cre-lox recombination technology. These mice were 
hyperphosphatemic with elevated serum FGF23 levels, indicating that distal tubular Klotho 
affects phosphate reabsorption in the proximal tubules. In contrast to Ksp-KL
-/-
 mice, β -KL-/- 
mice (systemic Klotho knockout mice) exhibited the phenotype of existing Klotho null mice 
confirming that the Klotho gene functions as anti-aging gene. The mechanism of this proposed 
distal-to-proximal tubular signaling remains to be explored (Study I).  
 
To further elucidate the role of renal Klotho in the development of aging phenotype, we 
generated mice with Klotho deleted throughout the nephron (Six2-KL
-/-
). Six2-KL
-/-
 mice were 
infertile, kyphotic, growth retarded and had a decreased life span, closely resembling the 
phenotype seen in systemic Klotho knockout mice. Further, the serum and urine biochemistries, 
low serum Klotho levels, as well as profound histological abnormalities, were indistinguishable 
from systemic Klotho knockout mice, unravelling the kidney as the principal contributor to 
circulating Klotho and as the mediator of Klotho anti-ageing traits (Study II).   
 
In order to prevail the significant controversies regarding the presence or absence of Klotho in 
the vascular system and whether the vascular tissue is directly responsive to FGF23 endocrine 
action, we analyzed the expression of the FGF23 co-receptor Klotho in mouse arteries and 
generated a novel mouse model, harboring a vascular smooth muscle cell-specific deletion of 
Klotho (Sm22-KL
-/-
). Arterial Klotho transcripts were detected at very low levels, whereas the 
corresponding protein levels were undetectable. FGF23-Klotho signaling was collectively absent 
in the mouse arteries, and the vascular phenotype was unaffected by FGF23 treatment. Thus, our 
data do not support direct, Klotho-dependent FGF23 vasculotoxicity although confirmative 
studies in humans are warranted (Study III).  
 
Lastly, to better define the role FGF23-Klotho axis in the regulation of inflammation, we utilized 
chemotherapy-based conditioning, (Bu)-cyclophosphamide (Cy) murine model for acute graft 
versus host disease (aGVHD). FGF23-Klotho axis was dysregulated in the aGVHD-induced 
kidney injury (AKI). Renal Klotho was ablated in aGVHD mice. Further, serum biochemistry 
was also indistinguishable in the LPS-induced AKI model. Thus, our findings demonstrate that 
FGF23-Klotho signalling is substantially disturbed in aGVHD which might contribute to the 
development AKI (Study IV). 
  
Taken together, the studies included in the present thesis substantially contribute to the 
understanding of the role FGF23-Klotho axis and its mechanism of action in several disease 
conditions. Urgent studies to identify current and novel therapeutic interventions that restitute 
the deranged FGF23-Klotho axis in CKD and the inflammatory disease, aGVHD-associated AKI 
and identify individuals who will benefit the most from such treatment are warranted. 
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